Kyowa Kirin gives Parkinson's drug another shot under SPA

Despite a long and troubled development history, Kyowa Hakko Kirin continues to believe in the therapeutic value of its Parkinson's disease drug istradefylline, and has just started a new international Phase III program with the first-in-class oral adenosine A2A receptor antagonist with an eye on trying again for a US approval.